Albiglutide shows efficacy in HbA1C control, fewer side effects

03/12/2014 | Medscape (free registration)

Research published in The Lancet Diabetes & Endocrinology found that type 2 diabetes patients who took once-weekly albiglutide attained significant reductions in HbA1C levels, comparable with those who were on once-daily liraglutide. "The data indicate that albiglutide is a reasonable alternative to other glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes. It has good efficacy and a better tolerability profile with less nausea," said researcher Dr. Richard E. Pratley.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN